Mustang Bio is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
Location: United States, Massachusetts, Worcester
Investors 3
Mentions in press and media 14
| Date | Title | Description |
| 06.02.2025 | Mustang Bio Announces Pricing of $8 Million Public Offering | WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potent... |
| 27.10.2024 | How Worcester is Emerging as a Tech and Biotech Center | Share Tweet Share Share Email Worcester, Massachusetts, has gained attention as an emerging hub for technology and biotechnology. Once known mainly for its industrial and manufacturing roots, Worcester is experiencing an economic and techno... |
| 02.05.2024 | Mustang Bio Announces Closing of $4 Million Public Offering | - |
| 30.04.2024 | Mustang Bio Announces Pricing of $4 Million Public Offering | WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies i... |
| 29.04.2024 | Mustang Bio Announces Pricing of $4 Million Public Offering | - |
| 11.03.2024 | Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | - |
| 11.03.2024 | Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights | WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies i... |
| 07.03.2024 | Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma | - |
| 03.08.2023 | Mustang Bio to Participate in Two August 2023 Investor Conferences | WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cure... |
| 08.03.2022 | Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital | WORCESTER, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cur... |
Show more